1.49
Scisparc Ltd stock is traded at $1.49, with a volume of 96,772.
It is up +2.05% in the last 24 hours and down -38.17% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$1.46
Open:
$1.41
24h Volume:
96,772
Relative Volume:
0.03
Market Cap:
$4.88M
Revenue:
$1.31M
Net Income/Loss:
$-7.47M
P/E Ratio:
-0.2066
EPS:
-7.2117
Net Cash Flow:
$-5.11M
1W Performance:
-9.15%
1M Performance:
-38.17%
6M Performance:
+403.38%
1Y Performance:
+598.55%
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SPRC
Scisparc Ltd
|
1.49 | 4.78M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.36 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.73 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
852.04 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.76 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Scisparc Ltd Stock (SPRC) Latest News
Aug Drivers: Is SciSparc Ltd stock oversold or undervaluedMarket Risk Summary & High Conviction Buy Zone Picks - moha.gov.vn
Market Wrap: Is SciSparc Ltd. stock oversold or undervaluedWeekly Gains Report & Verified Momentum Stock Ideas - moha.gov.vn
How strong is SciSparc Ltd. stock revenue growthJuly 2025 PostEarnings & Weekly Breakout Watchlists - Улправда
SciSparc (SPRC) Stock Price, Quote, News & History - Benzinga
Can SciSparc Ltd. stock deliver strong Q4 earningsMarket Sentiment Review & Daily Risk Controlled Trade Plans - Улправда
Is SciSparc Ltd. stock a smart buy before Fed meetingJuly 2025 PostEarnings & Low Risk Entry Point Guides - DonanımHaber
Why SciSparc Ltd. stock remains on watchlistsQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - DonanımHaber
Why analysts remain bullish on SciSparc Ltd. stockAnalyst Downgrade & Weekly Return Optimization Plans - DonanımHaber
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What analysts say about SciSparc Ltd stockStop Loss Placement Tips & Rapid Profit Portfolio - earlytimes.in
SciSparc Ltd. Announces $2.2 Million Securities Offering - MSN
SciSparc gets Nasdaq extension to regain compliance - MSN
Scisparc Ltd (SPRC) - MSN
SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech - MSN
SciSparc Shares Experience Pre-Bell Dip Following Quiet Session - timothysykes.com
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast - ts2.tech
Will SciSparc Ltd. stock outperform growth indexesJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
NeuroThera to acquire 55% stake in quantum computing bio data company - MSN
SciSparc Shares Slide After Revealing Plans to Acquire MUSE Endoscopic System IP - MSN
SciSparc’s NeuroThera Labs Eyes Quantum Leap with New Acquisition - TipRanks
SciSparc Ltd. Announces NeuroThera Labs' Planned Acquisition of Quantum Computing Bio Data Company - Quiver Quantitative
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - The Manila Times
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to - GlobeNewswire
SciSparc plans to enter GERD device market with IP portfolio acquisition - MSN
NeuroThera to acquire 55% stake in quantum computing bio data firm - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SciSparc (SPRC) Stock Analysis Report | Financials & Insights - Benzinga
SciSparc stock tumbles after announcing MUSE system acquisition plans By Investing.com - Investing.com UK
SciSparc Ltd. (SPRC) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
SciSparc stock tumbles after announcing MUSE system acquisition plans - Investing.com
SciSparc to acquire MUSE endoscopic system patents from Xylo By Investing.com - Investing.com Nigeria
SciSparc to acquire MUSE endoscopic system patents from Xylo - Investing.com
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio - The Manila Times
Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio - marketscreener.com
SciSparc Ltd. Signs Agreement to Acquire Patents and Intellectual Property for Innovative MUSE™ Endoscopic System from Xylo Technologies Ltd. - Quiver Quantitative
Scisparc Plans On Entering The Multi-Billion-Dollar Gerd Device Market With Acquisition Of An Approved IP Portfolio - TradingView
SciSparc acquires Xylo Technologies' innovative endoscopic portfolio - Indian Pharma Post
SciSparc Ltd. (SPRC) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SciSparc to acquire treasury of patents for medical endoscopy systems - MSN
Form 424B5 SciSparc Ltd. - StreetInsider
Is SciSparc Ltd a good long term investmentStock Buyback Announcements & Free Tap Rapid Wealth - earlytimes.in
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):